The purpose of this Cancer Center Support Grant is to reduce cancer incidence, morbidity and mortality by providing an organizational structure and administration which maximizes the quality and interdisciplinary nature of competitive funded cancer research activities at the City of Hope. The core grant provides the mechanisms for continuous planning and evaluation of the research programs of the Center in light of new research opportunities and a broad array of technical support via state-of-the-art shared facilities.
The specific aims are to: (1) stimulate collaborative research interactions between basic science and clinical investigators and among research groups in diverse areas of investigation; (2) facilitate and enhance interdisciplinary programs in basic and clinical research; (3) develop and support core research facilities to improve the effectiveness of the Center's research programs; (4) support the development of new investigators and new programs needed to maximize the contributions of the institution as a Cancer Center. The existence of an NCI-Designated Cancer Center at the City of Hope has enhanced the commitment to cancer research by the Board of Directors and senior scientific leadership of the City of Hope. The Board recently recruited a new director experienced in Cancer Center program development and administration and continues to provide exceptional financial support for renovation and construction of clinical and basic research facilities and support of research personnel. In turn, members of the Cancer Center have competed successfully for three program project grants (gene therapy; bone marrow transplantation for hematologic malignancies; and radioimmunotherapy of cancer), a drug discovery grant for the development and delivery of anti-viral RNA as treatments for AIDS; and two consortium grants for innovative, mechanistically oriented, Phase I and Phase II cancer therapeutic trials. Six outstanding young molecular biologists were recruited to expand the gene therapy program at a basic level. Two programs in the previous grant, Tumor and Cell Biology and Virology, have been eliminated and the outstanding components in each were merged into a new program in Molecular Carcinogenesis. The existing programs in Molecular Biology, Immunology, Hematology Malignancies and Clinical and Experimental Therapeutics have been enhanced. There are two new developing programs in Cancer Control and Prevention and Breast Cancer Research. Programs are supported by 12 cores.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA033572-19S3
Application #
6345710
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Program Officer
Ciolino, Henry P
Project Start
1981-07-01
Project End
2002-11-30
Budget Start
1999-08-01
Budget End
2002-11-30
Support Year
19
Fiscal Year
2000
Total Cost
$232,391
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Liu, Xuxiang; Cao, Minghui; Palomares, Melanie et al. (2018) Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res 20:127
Das, Sadhan; Reddy, Marpadga A; Senapati, Parijat et al. (2018) Diabetes Mellitus-Induced Long Noncoding RNA Dnm3os Regulates Macrophage Functions and Inflammation via Nuclear Mechanisms. Arterioscler Thromb Vasc Biol 38:1806-1820
Querfeld, Christiane; Leung, Samantha; Myskowski, Patricia L et al. (2018) Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunol Res 6:900-909
Chiuppesi, Flavia; Nguyen, Jenny; Park, Soojin et al. (2018) Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice. J Virol 92:
Petrossian, Karineh; Kanaya, Noriko; Lo, Chiao et al. (2018) ER?-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. Oncotarget 9:27736-27751
Al Malki, Monzr M; Nathwani, Nitya; Yang, Dongyun et al. (2018) Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1828-1835
Bosworth, Alysia; Goodman, Elizabeth L; Wu, Eric et al. (2018) The Minneapolis-Manchester Quality of Life Instrument: reliability and validity of the Adult Form in cancer survivors. Qual Life Res 27:321-332
Vu, Binh Thanh; Shahin, Sophia Allaf; Croissant, Jonas et al. (2018) Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Sci Rep 8:8524
Ambaye, Nigus; Chen, Chih-Hong; Khanna, Swati et al. (2018) Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1? (HIF1?) in Cells. Biochemistry 57:1807-1813
Li, Sihui; Ali, Shafat; Duan, Xiaotao et al. (2018) JMJD1B Demethylates H4R3me2s and H3K9me2 to Facilitate Gene Expression for Development of Hematopoietic Stem and Progenitor Cells. Cell Rep 23:389-403

Showing the most recent 10 out of 1396 publications